{"id":"buprenorphine-subutex","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Sweating"},{"rate":null,"effect":"Dizziness"}]},"_chembl":{"chemblId":"CHEMBL2368861","moleculeType":"Small molecule","molecularWeight":"504.11"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Buprenorphine has high affinity and partial agonist activity at the mu-opioid receptor, meaning it binds strongly but produces a submaximal response. This pharmacological profile creates a 'ceiling effect' that limits respiratory depression and overdose risk. It is used primarily for opioid use disorder maintenance treatment and pain management, where it suppresses withdrawal symptoms and reduces illicit opioid use.","oneSentence":"Buprenorphine is a partial opioid agonist that binds to mu-opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a lower risk of overdose compared to full opioid agonists.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:34.801Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Opioid use disorder (maintenance treatment)"},{"name":"Moderate to severe pain"}]},"trialDetails":[{"nctId":"NCT07435077","phase":"PHASE4","title":"Examining Analgesic Synergy and Efficacy in Trauma Care","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":282},{"nctId":"NCT07498322","phase":"NA","title":"Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2026-06-01","conditions":"Opiod Use Disorder","enrollment":271031},{"nctId":"NCT04677114","phase":"PHASE2","title":"Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections","status":"COMPLETED","sponsor":"Laura Fanucchi","startDate":"2021-03-16","conditions":"Drug Use, Opioid-use Disorder","enrollment":71},{"nctId":"NCT03745339","phase":"","title":"Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder","status":"RECRUITING","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2019-06-07","conditions":"Opioid-Related Disorders, Drug Addiction","enrollment":150},{"nctId":"NCT06496230","phase":"EARLY_PHASE1","title":"Open Trial of Technology-Enhanced Behavioral Intervention for Buprenorphine Retention in Pregnant and Postpartum People","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2024-08-06","conditions":"Opioid Use Disorder, Pregnancy Related","enrollment":15},{"nctId":"NCT06441604","phase":"PHASE2","title":"Extended-release Buprenorphine as a Novel Low-dose Induction Strategy","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2025-10-27","conditions":"Opioid Use Disorder","enrollment":30},{"nctId":"NCT07149870","phase":"NA","title":"Pain Management Teams Using Whole Health to Optimize Function and Safety in Veterans: The TEAMWORK Trial","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-11-20","conditions":"Chronic Pain","enrollment":432},{"nctId":"NCT06651177","phase":"PHASE2","title":"Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"T. John Winhusen, PhD","startDate":"2026-01-29","conditions":"Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":310},{"nctId":"NCT07485335","phase":"PHASE4","title":"A Bundled Intervention - Phase 2","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-09-07","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":160},{"nctId":"NCT05942313","phase":"","title":"Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy","status":"RECRUITING","sponsor":"Ilana Hull","startDate":"2023-08-28","conditions":"Opioid Use Disorder, Pregnancy Related","enrollment":100},{"nctId":"NCT06157840","phase":"NA","title":"Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-08-25","conditions":"Opioid Use Disorder, Poor Quality Sleep","enrollment":40},{"nctId":"NCT04587791","phase":"EARLY_PHASE1","title":"Cannabidiol in Opioid Use Disorder and Chronic Pain","status":"RECRUITING","sponsor":"Yale University","startDate":"2021-12-08","conditions":"Chronic Pain, Opioid Use Disorder","enrollment":34},{"nctId":"NCT06576843","phase":"PHASE2","title":"INDV-6001 Multiple-Dose Pharmacokinetic Study","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2024-09-17","conditions":"Moderate to Severe Opioid Use Disorder","enrollment":123},{"nctId":"NCT03911466","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Conceptual Model Assessments Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2020-07-21","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":97},{"nctId":"NCT03911739","phase":"","title":"Medication Treatment for Opioid Use Disorder in Expectant Mothers: Infant Neurodevelopmental Outcomes Sub-study","status":"COMPLETED","sponsor":"T. John Winhusen, PhD","startDate":"2021-06-14","conditions":"Opioid-Related Disorders, Drug Addiction, Pregnancy Related","enrollment":71},{"nctId":"NCT07475728","phase":"","title":"EMS-Initiated Buprenorphine","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Opioid Use Disorder","enrollment":495},{"nctId":"NCT07469501","phase":"PHASE4","title":"Comparing Outpatient Treatment Retention Among Individuals Using Fentanyl Randomized to Low-dose and Direct-to-inject Buprenorphine Initiation","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-06","conditions":"Opioid Use Disorder, Fentanyl","enrollment":50},{"nctId":"NCT05722561","phase":"PHASE2","title":"E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2024-08-08","conditions":"Opioid Use Disorder, Cigarette Smoking","enrollment":302},{"nctId":"NCT07278518","phase":"NA","title":"Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-05-19","conditions":"Opioid Use Disorder","enrollment":20},{"nctId":"NCT06784180","phase":"PHASE4","title":"Intrathecal Hydromorphone vs Intrathecal Morphine to Treat Post Cesarean Pain in Patients With Opioid Use Disorder Taking Buprenorphine","status":"WITHDRAWN","sponsor":"University of North Carolina, Chapel Hill","startDate":"2026-02","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT06341608","phase":"NA","title":"Improving Access to Opioid Use Disorder Treatment Among Marginalized Patients With a Tailored Telehealth Intervention","status":"NOT_YET_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-04-15","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT06948890","phase":"NA","title":"Effect of Music on Cue Reactivity for Patients With Opioid Use Disorder","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2025-04-20","conditions":"Opioid Use Disorder","enrollment":28},{"nctId":"NCT06367387","phase":"PHASE4","title":"Pain Self-Management and Patient-Oriented Dosing for Pain and in Retention Opioid Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Erin Winstanley","startDate":"2024-05-28","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":268},{"nctId":"NCT07420283","phase":"PHASE2","title":"A Study of Brenipatide in Participants With Opioid Use Disorder","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02-13","conditions":"Opioid Use Disorder","enrollment":465},{"nctId":"NCT06726200","phase":"EARLY_PHASE1","title":"A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use","status":"RECRUITING","sponsor":"Rachel R. Luba","startDate":"2026-08","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT06628622","phase":"PHASE1","title":"A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2025-01-27","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT02345655","phase":"NA","title":"On-site Evaluation of Substances Consumption on Opiate Maintenance","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2016-04-11","conditions":"Opiate Addiction","enrollment":42},{"nctId":"NCT07232641","phase":"","title":"Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic","status":"NOT_YET_RECRUITING","sponsor":"Boston University","startDate":"2026-04","conditions":"Substance Use Disorders, Alcohol Use Disorder, Opioid Use Disorder","enrollment":185810},{"nctId":"NCT07439549","phase":"PHASE4","title":"Symptom-Inhibited Naloxone Induction (SINI) for Buprenorphine Initiation: A Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Pouya Azar","startDate":"2026-02-18","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT07434427","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Intravenous Buprenorphine Administered Via PCA System Versus Oxycodone in the Management of Postoperative Pain After Video-Assisted Thoracoscopic Surgery","status":"NOT_YET_RECRUITING","sponsor":"Medical University of Silesia","startDate":"2026-02","conditions":"Acute Postoperative Pain, Chronic Postoperative Pain, Toracosurgery","enrollment":200},{"nctId":"NCT07278375","phase":"","title":"Target Trial Emulation for Pharmacologic Treatment of Neonatal Opioid Withdrawal Syndrome","status":"RECRUITING","sponsor":"HELP for NOWS Consortium","startDate":"2025-12-09","conditions":"Neonatal Opioid Withdrawal Syndrome","enrollment":796},{"nctId":"NCT07097493","phase":"PHASE4","title":"Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2026-04","conditions":"Knee Arthroplasty, Total","enrollment":90},{"nctId":"NCT07430345","phase":"PHASE1, PHASE2","title":"Buprenorphine for Analgesia in Older Adults With Acute Fractures in the Emergency Department: a Randomized Controlled Study","status":"NOT_YET_RECRUITING","sponsor":"The Cooper Health System","startDate":"2026-04","conditions":"Fracture","enrollment":48},{"nctId":"NCT07178158","phase":"NA","title":"Enhancing Addiction Treatment Through Psychoeducation","status":"NOT_YET_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-05-01","conditions":"Substance Use Disorders","enrollment":40},{"nctId":"NCT06593093","phase":"PHASE1, PHASE2","title":"A Bundled Intervention","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-02-13","conditions":"Opioid Use Disorder, Opioid Overdose","enrollment":190},{"nctId":"NCT06005662","phase":"PHASE2","title":"Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder","status":"WITHDRAWN","sponsor":"Johns Hopkins University","startDate":"2027-04","conditions":"Opioid Use Disorder","enrollment":""},{"nctId":"NCT07024498","phase":"NA","title":"Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-03-01","conditions":"Opioid Use Disorder","enrollment":3492},{"nctId":"NCT06187064","phase":"NA","title":"Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington","status":"COMPLETED","sponsor":"University of Washington","startDate":"2024-03-18","conditions":"Opioid Use Disorder, HIV Infections, Chlamydia","enrollment":50},{"nctId":"NCT06827288","phase":"NA","title":"Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder","status":"RECRUITING","sponsor":"RAND","startDate":"2024-10-04","conditions":"Opioid Use Disorder","enrollment":500},{"nctId":"NCT07421102","phase":"EARLY_PHASE1","title":"Pilot of Mailing Buprenorphine","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-02","conditions":"Opioid Use Disorder","enrollment":20},{"nctId":"NCT05991622","phase":"PHASE2","title":"Combined Injectable Treatment for HIV and OUD","status":"WITHDRAWN","sponsor":"Rhode Island Hospital","startDate":"2022-04-01","conditions":"Human Immunodeficiency Virus, Opioid Use Disorder","enrollment":""},{"nctId":"NCT06854029","phase":"PHASE4","title":"NOTRE: Optimizing Long-Acting Pre-Exposure Prophylaxis and Medications for Opioid Use Disorder Interventions in Carceral Settings","status":"NOT_YET_RECRUITING","sponsor":"Duke University","startDate":"2026-06","conditions":"HIV Infections, Opioid Use Disorder, Incarceration; Lens","enrollment":300},{"nctId":"NCT04245423","phase":"NA","title":"The Whole Health Study: Collaborative Care for OUD and Mental Health Conditions","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2020-12-15","conditions":"Opioid-use Disorder, Mental Health Conditions","enrollment":567},{"nctId":"NCT04276259","phase":"PHASE4","title":"Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses","status":"COMPLETED","sponsor":"Marta Peciña, MD PhD","startDate":"2020-10-19","conditions":"Major Depressive Disorder, Depression","enrollment":120},{"nctId":"NCT07148206","phase":"PHASE3","title":"Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","startDate":"2026-05","conditions":"Opioid Use Disorder","enrollment":40},{"nctId":"NCT03511118","phase":"","title":"Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants","status":"RECRUITING","sponsor":"Duke University","startDate":"2018-10-04","conditions":"Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI","enrollment":1600},{"nctId":"NCT07044466","phase":"NA","title":"Social Functioning in Opioid Use Disorder","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-02-23","conditions":"Opioid Use Disorder","enrollment":230},{"nctId":"NCT04995029","phase":"PHASE4","title":"Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2021-10-26","conditions":"Moderate to Severe Opioid-use Disorder","enrollment":785},{"nctId":"NCT06102200","phase":"NA","title":"An Integrated Intervention Involving Recovery Coaching and Cognitive Behavioral Therapy for Opioid Use Disorder","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2023-10-05","conditions":"Standard of Care, Standard of Care + CBT4CBT, Standard of Care + CBT4CBT + RC","enrollment":92},{"nctId":"NCT07176351","phase":"PHASE4","title":"Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic","status":"NOT_YET_RECRUITING","sponsor":"Yale University","startDate":"2026-03","conditions":"Opioid Use Disorder","enrollment":60},{"nctId":"NCT05051644","phase":"PHASE1","title":"An Adaptive Walking Intervention to Manage Chronic Pain in Veterans With Opioid Use Disorder Engaged in Opioid Agonist Treatment","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2022-04-01","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":60},{"nctId":"NCT03616236","phase":"PHASE3","title":"Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment","status":"SUSPENDED","sponsor":"Friends Research Institute, Inc.","startDate":"2022-07-01","conditions":"Opioid Use","enrollment":320},{"nctId":"NCT06306443","phase":"PHASE3","title":"Buprenorphine for Individuals in Jail","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-07-01","conditions":"Opioid Use Disorder","enrollment":240},{"nctId":"NCT05333341","phase":"NA","title":"Pain Care at Home to Amplify Function (Pain CHAMP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2023-06-16","conditions":"Opioid Use Disorder, Opioid Misuse, Chronic Pain","enrollment":259},{"nctId":"NCT07361432","phase":"PHASE3","title":"Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-11-02","conditions":"Opioid Use Disorder, Chronic Pain","enrollment":250},{"nctId":"NCT04408313","phase":"PHASE2, PHASE3","title":"Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail","status":"ACTIVE_NOT_RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2020-10-28","conditions":"Opioid-use Disorder","enrollment":240},{"nctId":"NCT05063201","phase":"PHASE2","title":"Cariprazine for Comorbid Cocaine and Opioid Use Disorder","status":"COMPLETED","sponsor":"Kyle Kampman","startDate":"2022-08-05","conditions":"Opioid-use Disorder, Cocaine Use Disorder","enrollment":26},{"nctId":"NCT05878210","phase":"","title":"Evaluating the SUBLOCADE Treatment Exit Strategy","status":"COMPLETED","sponsor":"Indivior Inc.","startDate":"2023-11-24","conditions":"Opioid Use Disorder","enrollment":12},{"nctId":"NCT04771689","phase":"PHASE4","title":"Buprenorphine/Naloxone Micro-Dosing for Postoperative Pain Management in Opioid-Tolerant Patients","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2022-07-01","conditions":"Post-operative Pain","enrollment":""},{"nctId":"NCT07342504","phase":"NA","title":"Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment","status":"RECRUITING","sponsor":"University of Notre Dame","startDate":"2026-01-21","conditions":"Alcohol Use Disorder, Opioid Use Disorder, Alcohol Use","enrollment":60},{"nctId":"NCT07001371","phase":"NA","title":"Emotional Brain Training for Addiction Medicine Treatment - A Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Loma Linda University","startDate":"2026-03","conditions":"Cannabis Use Disorder, Stimulant Use Disorder, Opioid Use Disorder","enrollment":54},{"nctId":"NCT07338084","phase":"","title":"OpioidRedoxStudyII","status":"NOT_YET_RECRUITING","sponsor":"EPC Education s.r.o.","startDate":"2026-06-30","conditions":"Oxidative Stress, Opioid Use","enrollment":120},{"nctId":"NCT04601064","phase":"NA","title":"Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-04-20","conditions":"HIV Infections, Substance Use Disorders, Mental Health Disorder","enrollment":405},{"nctId":"NCT05988710","phase":"PHASE4","title":"Low-dose Buccal Buprenorphine: Relative Abuse Potential and Analgesia","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2023-10-19","conditions":"Analgesia, Abuse Opioids, Pain","enrollment":120},{"nctId":"NCT04375033","phase":"PHASE4","title":"A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-11-03","conditions":"Opioid Use Disorder","enrollment":952},{"nctId":"NCT06008990","phase":"","title":"Maternal Brain Imaging in Opioid Use Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Indiana University","startDate":"2023-08-15","conditions":"Opioid Use Disorder, Substance-Related Disorders, Substance Use","enrollment":40},{"nctId":"NCT03698669","phase":"NA","title":"Treating Chronic Pain in Buprenorphine Patients in Primary Care Settings","status":"COMPLETED","sponsor":"Boston University","startDate":"2019-08-21","conditions":"Opioid-Related Disorders","enrollment":163},{"nctId":"NCT04251819","phase":"PHASE2, PHASE3","title":"Buprenorphine Plus Baclofen to Increase Analgesia in Healthy Volunteers","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2021-01-21","conditions":"Acute Pain, Analgesia","enrollment":19},{"nctId":"NCT07314346","phase":"PHASE1","title":"Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone","status":"NOT_YET_RECRUITING","sponsor":"Atea Pharmaceuticals, Inc.","startDate":"2025-12","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT04091009","phase":"PHASE4","title":"Effect of Standard of Care Reduced Dose Versus Full Dose Buprenorphine/Naloxone in the Perioperative Period on Pain Control and Post-Operative Opioid Use Disorder Symptoms","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2019-10","conditions":"Opioid-use Disorder, Opioid Use Disorder, Mild","enrollment":""},{"nctId":"NCT06023459","phase":"PHASE3","title":"Extended-release Buprenorphine Compared to Sublingual Buprenorphine in Rural Settings (RXR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yih-Ing Hser","startDate":"2024-10-14","conditions":"Opioid-Related Disorders, Substance-Related Disorders, Narcotic-Related Disorders","enrollment":144},{"nctId":"NCT05546515","phase":"PHASE2","title":"Suvorexant for Opioid/Stimulant Co-use","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2022-12-01","conditions":"Opioid Use Disorder, Stimulant Use Disorder","enrollment":20},{"nctId":"NCT07296770","phase":"PHASE3","title":"An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-05-01","conditions":"Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery","enrollment":126},{"nctId":"NCT06130501","phase":"NA","title":"tAN for PTSD and OUD in Buprenorphine Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2024-07-01","conditions":"Posttraumatic Stress Disorder, Opioid Use Disorder","enrollment":20},{"nctId":"NCT07079826","phase":"NA","title":"Sparrow Link Neuromodulation Device for Opioid Withdrawal Management in Hospitalized Adults With Opioid Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"Payel Roy","startDate":"2026-02-21","conditions":"Opioid Withdrawal, Opioid Use Disorder (OUD)","enrollment":50},{"nctId":"NCT06027814","phase":"NA","title":"MHealth Incentivized Adherence Plus Patient Navigation","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-01-03","conditions":"Opioid Use Disorder, Medication Adherence, Polysubstance Drug Use (Indiscriminate Drug Use)","enrollment":40},{"nctId":"NCT03923374","phase":"","title":"Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes","status":"RECRUITING","sponsor":"Senthil Sadhasivam","startDate":"2018-09-15","conditions":"Opioid-use Disorder, Opioid Use, Unspecified, Buprenorphine Dependence","enrollment":600},{"nctId":"NCT04464980","phase":"PHASE2","title":"Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2021-06-08","conditions":"Opioid Use Disorder (OUD)","enrollment":1516},{"nctId":"NCT06355778","phase":"NA","title":"Adversity, Brain and Opioid Use Study","status":"RECRUITING","sponsor":"University of Michigan","startDate":"2025-01-09","conditions":"Opioid Use Disorder, Healthy","enrollment":185},{"nctId":"NCT03150173","phase":"PHASE2","title":"Onsite Buprenorphine Treatment at Syringe Exchange Programs","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2019-01-02","conditions":"Opiate Addiction","enrollment":97},{"nctId":"NCT06526286","phase":"","title":"Clinical Decision Support to Increase Use of Medications for Opioid Use Disorder","status":"NOT_YET_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2026-02","conditions":"Medication Abuse, Harm Reduction, Opioid Use Disorder","enrollment":200000},{"nctId":"NCT04345718","phase":"PHASE2, PHASE3","title":"EXHIT ENTRE Comparative Effectiveness Trial","status":"COMPLETED","sponsor":"Gavin Bart","startDate":"2021-08-09","conditions":"Substance Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe","enrollment":344},{"nctId":"NCT04464421","phase":"NA","title":"SMART Effectiveness Trial","status":"COMPLETED","sponsor":"Karen Derefinko, PhD","startDate":"2020-08-17","conditions":"Opioid-use Disorder, Opioid Dependence, Treatment Adherence","enrollment":48},{"nctId":"NCT06593353","phase":"NA","title":"Systems Analysis and Improvement to Optimize Opioid Use Disorder Care Quality and Continuity for Patients Exiting Jail","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-11-21","conditions":"Opioid Use Disorder, Opioid Use Disorders","enrollment":4165},{"nctId":"NCT07262190","phase":"NA","title":"NavSTAR Implementation Effectiveness Trial Across a Health System","status":"RECRUITING","sponsor":"Friends Research Institute, Inc.","startDate":"2025-10-27","conditions":"Opioid Use Disorder","enrollment":720},{"nctId":"NCT06416020","phase":"NA","title":"Integrating MOUD in Nonmedical Community Settings (Better Together)","status":"NOT_YET_RECRUITING","sponsor":"Howard University","startDate":"2026-01-26","conditions":"Opioid Use Disorder","enrollment":400},{"nctId":"NCT07251283","phase":"NA","title":"Food Insecurity and Eating Behavior Among Adults Receiving Buprenorphine or Methadone Maintenance Treatment: Pilot Study 2","status":"RECRUITING","sponsor":"University of Vermont","startDate":"2025-11-07","conditions":"Food Security","enrollment":40},{"nctId":"NCT05076370","phase":"EARLY_PHASE1","title":"Safety and Tolerability of Cannabidiol Among Persons With Opioid Use Disorder Receiving Methadone or Buprenorphine","status":"COMPLETED","sponsor":"Yale University","startDate":"2021-12-08","conditions":"Addiction","enrollment":7},{"nctId":"NCT06999811","phase":"NA","title":"Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-11-05","conditions":"Opioid Use Disorder, Pregnancy","enrollment":37},{"nctId":"NCT05270434","phase":"NA","title":"Optimal Timing of Endoscopic Intervention in the Treatment of Chronic Pancreatitis.","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2025-03-12","conditions":"Pancreatitis, Chronic","enrollment":220},{"nctId":"NCT06774248","phase":"NA","title":"Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD","status":"RECRUITING","sponsor":"Potomac Health Foundations","startDate":"2025-02-01","conditions":"Opioid Use Disorder","enrollment":80},{"nctId":"NCT06442566","phase":"PHASE1, PHASE2","title":"ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2024-08-12","conditions":"Opioid Withdrawal, Chronic Pain","enrollment":240},{"nctId":"NCT06574009","phase":"PHASE4","title":"Better Options for Chronic Cancer Pain","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2025-10-07","conditions":"Chronic Pain, Cancer Survivor, Opioid Dependence","enrollment":294},{"nctId":"NCT06732596","phase":"NA","title":"Sustaining Recovery for People on Opioid Agonist Treatment With Conversational Agents","status":"RECRUITING","sponsor":"Boston Medical Center","startDate":"2025-10-30","conditions":"Opioid Use Disorder","enrollment":100},{"nctId":"NCT05118204","phase":"PHASE4","title":"Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization","status":"TERMINATED","sponsor":"Montefiore Medical Center","startDate":"2022-09-29","conditions":"Substance Use Disorders, Opioid-use Disorder, Chronic Pain","enrollment":23},{"nctId":"NCT05339256","phase":"PHASE2","title":"Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual","status":"NOT_YET_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2026-02-01","conditions":"Opioid Use Disorder","enrollment":50},{"nctId":"NCT06323824","phase":"PHASE4","title":"Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-06-04","conditions":"Opioid Use Disorder","enrollment":600},{"nctId":"NCT06316830","phase":"PHASE2, PHASE3","title":"Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose","status":"RECRUITING","sponsor":"Rhode Island Hospital","startDate":"2025-01-06","conditions":"Opioid Use Disorder","enrollment":250},{"nctId":"NCT06384781","phase":"NA","title":"STAMPS: South Carolina Buprenorphine Treatment Initiation, Adherence, and Retention Utilizing Mobile Health Units and Peer Support Specialists","status":"COMPLETED","sponsor":"Prisma Health-Upstate","startDate":"2024-05-02","conditions":"Opioid Use Disorder","enrollment":90},{"nctId":"NCT06086275","phase":"PHASE1","title":"Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2024-06-04","conditions":"Opioid Use Disorder","enrollment":18}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"AMNESIA"},{"count":1,"reaction":"APNOEA"},{"count":1,"reaction":"ASPIRATION"},{"count":1,"reaction":"BLOOD CULTURE POSITIVE"},{"count":1,"reaction":"CITROBACTER TEST POSITIVE"},{"count":1,"reaction":"CONFUSIONAL STATE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"DIZZINESS"},{"count":1,"reaction":"DRUG HYPERSENSITIVITY"}],"_approvalHistory":[],"publicationCount":100,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Subutex"],"phase":"marketed","status":"active","brandName":"Buprenorphine (Subutex)","genericName":"Buprenorphine (Subutex)","companyName":"Indivior Inc.","companyId":"indivior-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Buprenorphine is a partial opioid agonist that binds to mu-opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a lower risk of overdose compared to full opioid agonists. Used for Opioid use disorder (maintenance treatment), Moderate to severe pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}